Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-08-19 Purchase |
2024-08-21 6:38 pm |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
38,924 | $0.62085 | $24,166 | 296,540 (Direct) |
View |
| 2023-08-08 Purchase |
2023-08-09 6:21 pm |
Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer |
71,762 | $1.22 | $87,550 | 201,555 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-28 Option Award |
2025-02-11 5:41 pm |
N/A 2035-01-27 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CBO, COO and CCO |
450,000 | $0 | 450,000 (Direct) |
View |
| 2024-06-04 Exercise |
2024-06-05 2:37 pm |
N/A N/A |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
56,061 | $0.55 | 305,055 (Direct) |
View |
| 2024-06-04 Exercise |
2024-06-05 2:37 pm |
N/A 2032-03-27 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
56,061 | $0 | 305,055 (Direct) |
View |
| 2024-02-01 Option Award |
2024-02-02 5:53 pm |
N/A 2034-01-31 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan CHIEF BUSINESS OFFICER AND COO |
600,000 | $0 | 600,000 (Direct) |
View |
| 2023-10-24 Option Award |
2023-10-26 5:54 pm |
N/A 2033-10-23 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer and COO |
75,000 | $0 | 75,000 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 6:29 pm |
N/A 2033-01-31 |
Quince Therapeutics Inc. | QNCX | Hannah Brendan Chief Business Officer |
225,000 | $0 | 225,000 (Direct) |
View |
| 2022-05-19 Option Award(A) |
2022-05-27 5:34 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Hannah Brendan Chief Business Officer |
113,569 | $0 | 129,793 (Direct) |
View |
| 2022-05-19 Option Award |
2022-05-23 8:07 pm |
N/A 2032-03-27 |
Cortexyme Inc. | CRTX | Hannah Brendan Chief Business Officer |
473,380 | $0 | 473,380 (Direct) |
View |